Gossamer Bio, Inc.·4

Oct 2, 4:13 PM ET

Hasnain Faheem 4

4 · Gossamer Bio, Inc. · Filed Oct 2, 2025

Insider Transaction Report

Form 4
Period: 2025-10-01
Hasnain Faheem
DirectorPresident & CEO
Transactions
  • Award

    Common Stock

    2025-10-01+437,500557,793 total
Holdings
  • Common Stock

    (indirect: By Trust)
    5,408,073
Footnotes (1)
  • [F1]Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer.

Documents

1 file
  • 4
    wk-form4_1759435995.xmlPrimary

    FORM 4